1. Home
  2. CMPX vs DLX Comparison

CMPX vs DLX Comparison

Compare CMPX & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • DLX
  • Stock Information
  • Founded
  • CMPX 2014
  • DLX 1915
  • Country
  • CMPX United States
  • DLX United States
  • Employees
  • CMPX N/A
  • DLX N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • DLX Advertising
  • Sector
  • CMPX Health Care
  • DLX Consumer Discretionary
  • Exchange
  • CMPX Nasdaq
  • DLX Nasdaq
  • Market Cap
  • CMPX 730.9M
  • DLX 719.5M
  • IPO Year
  • CMPX N/A
  • DLX N/A
  • Fundamental
  • Price
  • CMPX $4.03
  • DLX $19.42
  • Analyst Decision
  • CMPX Strong Buy
  • DLX Strong Buy
  • Analyst Count
  • CMPX 7
  • DLX 1
  • Target Price
  • CMPX $14.71
  • DLX $23.00
  • AVG Volume (30 Days)
  • CMPX 1.9M
  • DLX 225.9K
  • Earning Date
  • CMPX 11-11-2025
  • DLX 11-05-2025
  • Dividend Yield
  • CMPX N/A
  • DLX 6.21%
  • EPS Growth
  • CMPX N/A
  • DLX 49.73
  • EPS
  • CMPX N/A
  • DLX 1.28
  • Revenue
  • CMPX N/A
  • DLX $2,106,724,000.00
  • Revenue This Year
  • CMPX N/A
  • DLX $0.20
  • Revenue Next Year
  • CMPX N/A
  • DLX $1.65
  • P/E Ratio
  • CMPX N/A
  • DLX $15.06
  • Revenue Growth
  • CMPX N/A
  • DLX N/A
  • 52 Week Low
  • CMPX $1.27
  • DLX $13.61
  • 52 Week High
  • CMPX $4.86
  • DLX $24.45
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 53.07
  • DLX 58.09
  • Support Level
  • CMPX $3.86
  • DLX $17.82
  • Resistance Level
  • CMPX $4.86
  • DLX $18.81
  • Average True Range (ATR)
  • CMPX 0.31
  • DLX 0.45
  • MACD
  • CMPX -0.05
  • DLX 0.08
  • Stochastic Oscillator
  • CMPX 38.43
  • DLX 96.93

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

About DLX Deluxe Corporation

Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.

Share on Social Networks: